New Features, Additional Keynote Speakers Will Round Out 11th Annual Cardiometabolic Health Congress

Boston, September 27, 2016 – Continuing its dedication to translating late-breaking clinical research on cardiometabolic risk reduction into practical and targeted education, the Cardiometabolic Health Congress will hold its 11th Annual CMHC from October 5-8, 2016 at the Sheraton in Boston, MA.

New features of the CMHC this year include two Practice Management workshops (“Capital – What Healthcare Professionals Need to Know About Money” and “Leadership and Management for Healthcare Professionals”) and a symposium on nutritional interventions in clinical practice, all taking place on Wednesday, October 5.

There will be a total of 5 keynotes during this year’s CMHC. The General Sessions, which also begin on Wednesday, October 5, will kick off with a keynote by Dr. Steven Nissen titled “Intravascular Ultrasound Insights into the Regression and Progression of Coronary Atherosclerosis.” Other keynotes will be presented by Dr. Peter Libby, speaking on the increasing prevalence of triglycerides as a cardiovascular risk factor; Dr. Suzanne Oparil presenting an update and clinical implications of the SPRINT trial; Dr. C. Ronald Kahn discussing the gut microbiome as a modifier of insulin resistance and metabolic syndrome; and Dr. Subodh Verma lending his insight on obesity fat distribution and cardiovascular risk.

Featured sessions on Thursday, October 6 include “Late-Breaking Clinical Trials and FDA Update,” moderated by Christie M. Ballantyne, MD and joined by Deepak L. Bhatt, MD, Robert H. Eckel, MD, Keith C. Ferdinand, MD, and Jay S. Skyler, MD. Dr. Bhatt will also moderate the debate, “The Latest in Antithrombotic Therapy: The Experts Take Sides,” with Kenneth Mahaffey, MD and Gregg W. Stone, MD during the session on Dyslipidemia, Atherosclerosis and Cardiovascular Disease Risk Reduction.

Dr. Clyde Yancy will discuss heart failure in the context of SPRINT during the Hypertension, Cardio-Renal, and Heart Failure session on Friday, October 7 and Dr. George Bakris will offer perspective on SGLT-2 inhibitors as second-line therapy. The Diabetes session taking place later that day will feature presentations on the results of CV outcomes trials and diabetes therapies, the implications of recent trials on the management of diabetes, and future directions of insulin and non-insulin therapies.

Coming to a conclusion on Saturday, October 8 with a session focusing on Obesity, Lifestyle Management, and Cardiovascular Disease, highlights will include Drs. Lee Kaplan and Francesco Rubino presenting the newest evidence on metabolic surgery and Dr. Caroline Apovian discussing the latest information on obesity treatments and pharmacology guidelines for clinicians.

“This conference has it all, from emerging research to the latest clinical guidelines to putting that knowledge into everyday practice,” Atul Soreng, MD, has said.

For a complete list of speakers, agenda, and registration details for the 11th Annual Cardiometabolic Health Congress visit: https://www.cardiometabolichealth.org/2016/index.html or call 877-571-4700.